Phosphoethanolamine-complexed C-reactive protein: A pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum

Clinica Chimica Acta

Volumn 394, Issue 1-2, 2008, Pages 94-98

  Singh, Sanjay K ^a   Suresh, Madathilparambil V ^a   Prayther, Deborah C ^a   Moorman, Jonathan P ^a   Rusiñol, Antonio E ^a   Agrawal, Alok ^a  

^a East Tennessee State University   (United States)

Author keywords

C reactive protein; Cholesterol; Low density lipoprotein; Phosphocholine; Phosphoethanolamine

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; C REACTIVE PROTEIN PHOSPHOETHANOLAMINE COMPLEX; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOETHANOLAMINE;

ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; BINDING SITE; HUMAN; LIQUID; PRIORITY JOURNAL; PROTEIN INTERACTION; SERUM; SUCROSE DENSITY GRADIENT CENTRIFUGATION;

C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ETHANOLAMINES; HUMANS; PROTEIN BINDING;

EID: 44649127287     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.04.015     Document Type: Article

References (36)

1. Singh S.K., Suresh M.V., Voleti B., and Agrawal A. The connection between C-reactive protein and atherosclerosis. Ann Med 40 (2008) 110-120
2. Sjowall C., and Wettero J. Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins. Clin Chim Acta 378 (2007) 13-23
3. De Ferranti S., and Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta 317 (2002) 1-15
4. Shrive A.K., Cheetham G.M.T., Holden D., et al. Three dimensional structure of human C-reactive protein. Nature Struct Biol 3 (1996) 346-354
5. Volanakis J.E., and Kaplan M.H. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med 136 (1971) 612-614
6. Agrawal A., Simpson M.J., Black S., Carey M.P., and Samols D. A C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide. J Immunol 169 (2002) 3217-3222
7. Suresh M.V., Singh S.K., Ferguson Jr. D.A., and Agrawal A. Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide. J Immunol 178 (2007) 1158-1163
8. Kushner I., Rakita L., and Kaplan M.H. Studies of acute-phase protein. II. localization of Cx-reactive protein in heart in induced myocardial infarction in rabbits. J Clin Invest 42 (1963) 286-292
9. Lagrand W.K., Niessen H.W.M., Wolbink G.J., et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 95 (1997) 97-103
10. Pepys M.B., Hirschfield G.M., Tennent G.A., et al. Targeting CRP for the treatment of cardiovascular disease. Nature 440 (2006) 1217-1221
11. Thompson D., Pepys M.B., and Wood S.P. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 7 (1999) 169-177
12. Coll J.M. Immunochemical recognition of the binding of C-reactive protein to solid-phase phosphorylethanolamine. Rev Espanol Fisiol 44 (1988) 169-178
13. Oliveira E.B., Gotschlich E.C., and Liu T.Y. Comparative studies on the binding properties of human and rabbit C-reactive proteins. J Immunol 124 (1980) 1396-1402
14. Schwalbe R.A., Dahlbäck B., Coe J.E., and Nelsestuen G.L. Pentraxin family of proteins interacts specifically with phosphorylcholine and/or phosphorylethanolamine. Biochemistry 31 (1992) 4907-4915
15. Chang M.K., Binder C.J., Torzewski M., and Witztum J.L. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 99 (2002) 13043-13048
16. Bhakdi S., Torzewski M., Klouche M., and Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 19 (1999) 2348-2354
17. Biró A., Thielens N.M., Cervenák L., Prohászka Z., Füst G., and Arlaud G.J. Modified low density lipoproteins differentially bind and activate the C1 complex of complement. Mol Immunol 44 (2006) 1169-1177
18. Ji S.R., Wu Y., Potempa L.A., Qiu Q., and Zhao J. Interactions of C-reactive protein with low-density lipoproteins: implications for an active role of modified C-reactive protein in atherosclerosis. Int J Biochem Cell Biol 38 (2006) 648-661
19. Taskinen S., Kovanen P.T., Jarva H., Meri S., and Pentikainen M.O. Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem J 367 (2002) 403-412
20. Van Tits L., De Graff J., Toenhake H., Van Heerde W., and Stalenhoef A. C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 25 (2005) 717-722
21. Reynolds G.D., and Vance R.P. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med 111 (1987) 265-269
22. Sun H., Koike T., Ichikawa T., et al. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol 167 (2005) 1139-1148
23. Torzewski M., Rist C., Mortensen R.F., et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 20 (2000) 2094-2099
24. De Beer F.C., Soutar A.K., Baltz M.L., Trayner I.M., Feinstein A., and Pepys M.B. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med 156 (1982) 230-242
25. Fu T., and Borensztajn J. Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem J 366 (2002) 195-201
26. Nunomura W., and Hatakeyama M. Binding of low density lipoprotein (LDL) to C-reactive protein (CRP): a possible binding through apolipoprotein B in LDL at phosphorylcholine-binding site of CRP. Hokkaido J Med Sci 65 (1990) 474-480
27. Singh S.K., Suresh M.V., Prayther D.C., Moorman J.P., Rusinol A.E., and Agrawal A. C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells. J Immunol 180 (2008) 4316-4322
28. Brown A.J., Leong S.L., Dean R.T., and Jessup W. 7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. J Lipid Res 38 (1997) 1730-1745
29. Muller H., Hellgren L.I., Olsen E., and Skrede A. Lipids rich in phosphatidylethanolamine from natural gas-utilizing bacteria reduce plasma cholesterol and classes of phospholipids: a comparison with soybean oil. Lipids 39 (2004) 833-841
30. Brown M.S., and Goldstein J.L. Lowering LDL: not only how low, but how long?. Science 311 (2006) 1721-1723
31. Devaraj S., Rogers J., and Jialal I. Statins and biomarkers of inflammation. Curr Atheroscler Rep 9 (2007) 33-41
32. Voleti B., and Agrawal A. Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Mol Immunol 43 (2006) 891-896
33. Wang H.R., Li J.J., Huang C.X., and Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-a and activation of nuclear factor-kB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 353 (2005) 53-60
34. Rufail M.L., Ramage S.C., and Van Antwerpen R. C-reactive protein inhibits in vitro oxidation of low-density lipoprotein. FEBS Lett 580 (2006) 5155-5160
35. Kruth H.S., Huang W., Ishii I., and Zhang W.Y. Macrophage foam cell formation with native low density lipoprotein. J Biol Chem 277 (2002) 34573-34580
36. Kovacs A., Tornvall P., Nilsson R., Tegnér J., Hamsten A., and Björkegren J. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA 104 (2007) 13768-13773